You just read:

Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019

News provided by

Tolero Pharmaceuticals, Inc.

Jun 14, 2019, 11:30 ET